CMG at a glance

THE CZECH MYELOMA GROUP - INTRODUCTION AND HISTORICAL OVERVIEW

The Czech Myeloma Group (CMG) was established in 1996. The main objective of the CMG is to organize and coordinate research and clinical activities in the Czech Republic in the area of multiple myeloma. It ensures that the best current standards of care for patients with multiple myeloma are met. Its clinical studies provide the Czech patients with multiple myeloma the access to the latest experimental treatments in the field.

As the activities spread out, The Czech Myeloma Group Foundation was established in 2001 to give support to patient related activities and promotions.

All activities of The CMG and of its Foundation are directed at improvements of the treatment of multiple myeloma in the Czech Republic. Also, both organizations aim to provide a relief from the many problems and conditions that limit the quality of life of patients suffering from multiple myeloma.

 

A brief history of The CMG
1996 CMG founded
2001 CMG Foundation established
2003 Cooperation with The International Myeloma Foundation (IMF) initiated
2005 Communication among countries of Central and Eastern Europe within the new multicenter clinical trial started
2006 Independent Patient organization established
2006 Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre founded
2007 CMG became a partner of The IMF

 

FUNDAMENTAL PHILOSOPHY OF THE CMG AND THE CMG FOUNDATION

The CMG is an association of physicians and other researchers with main interest in scientific investigation, diagnostics and therapy of multiple myeloma and monoclonal gammopathy.

Goals:

 

The CMG Foundation is an association of healthcare givers formed to meet the special needs of patients suffering from multiple myeloma, their families and friends.

Goals:

 

THE CMG AND THE CMG FOUNDATION ACTIVITIES

Concentration on physicians and professional community

 

 

A brief activities focused on physicians
1996 The first multicentric study 4W started
2002 The second multicentric trial CMG 2002 initiated
2003 Guidelines for treatment of Multiple myeloma published
2005 Guidelines for treatment of Multiple myeloma upgraded
2007 Registry of monoclonal gammopathies opened
2007 Educational program CRAB (Toward a better quality of life through an earlier diagnosis) launched

 

Concentration on the patients

 

 

A brief activities focused on the patients 
2002 Model project of waiting room in out-patient clinic finished
2002 HOT-LINE installed
2002 The benefit performances held regularly
2003 Patients brochures published regularly in association with The IMF
2005 The first Patient & Family Seminar held  in Lednice
2006 Independent Patient organization established
2006 The second Patient & Family Seminar held  in Podebrady
2007 The third Patient & Family Seminar held  in Lednice

 

 

Treatments accessibility
1996 Autologous transplantation implemented to the treatment regimen
2002 More than 80% of patients indicated for autologous transplantation benefit from this treatment
2001 Thalidomide introduced in the Czech Republic
2004 Thalidomide reimbursed for relapsed patients
2004 Bortezomib introduced in the Czech Republic through Velcade  initiation  programME
2005 Bortezomib reimbursed for relapsed patients
2007 Thalidomide reimbursed for newly diagnosed patients
2007 Lenalidomide introduced in the Czech Republic through LENALIDOMIDE NAMED  PATIENT PROGRAMME

Concentration on research

The preclinical research was focused mainly on immunotherapy, development of anti-tumor vaccines respectively in the period 1998-2002. More complex research program, established in the year 2002, finally led to opening new Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre in Brno as the reference research centre of The Czech Myeloma Group. This centre works closely with academic field and participates in clinical activities of the Czech Myeloma Group which gives a great opportunity to promote research on multiple myeloma and monoclonal gammopathy. The centre connection with academic field and coordination with clinical activities of The Czech Myeloma Group gives a great opportunity to reinforce research of multiple myeloma and monoclonal gammopathy. The main research projects are focused on pharmocogenomics and proteomics.  

A brief preclinical research
1998 Laboratory of hematology and experimental immunotherapy founded
2003 The first anti-myeloma vaccine applied
2004 Biological sample bank and databases opened
2005 Project Bank on a Cure - participation in the Czech Republic initiated
2006 Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre founded

The clinical research is mainly directed at the autologous transplantation and the role of maintenance and/or consolidation therapy. It is also focused on the re-transplantation for relapsed patients and on the phase I / II studies using anti-tumor vaccines.

A brief clinical research - trials
Clinical trials conducted by the CMG
1996-2002 4W - maintenance th. after autologous transplantation in newly diagnosed pts.
2002-2007 CMG 2002 - maintenance or consolidation th. after autologous transplantation in newly diagnosed pts.
1998 T2 model - re-transplantation and experimental th. after transplantation
2003 Anti-myeloma vaccine (KLH-Id protein)
2005 Prognostic impact of genetic abnormalities in the area of new drugs
2006 Anti-myeloma vaccine (dendritic cells)

 

PRESENT PROJECTS AND PLANS FOR THE FUTURE

Education programs (EP):

 

CRAB - Toward a better quality of life through an earlier diagnosis
Program is focused on family physicians and key out-patients physicians responsible for recognizing the symptoms related to MM (specialists of rheumatology, neurology, orthopedic or nephrology).
Initiation: 2007
Duration: 2007-2011
Anticipated outcome:

Transfer of methods
Program is focused on the standardization of laboratory examination methods in multiple myeloma in Central and Eastern Europe (incl. Czech Republic, Slovakia, Poland and Hungary).
Guaranteed by Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre
Initiation: 2006
Outcome:

International workshops:

 

Register of Monoclonal Gammopathies (RMG register)

Project MGUS 2007 - "2000 data sets in 2 year"
Initiation: 2007
Data-info part: follow up steps

Targets:

Research part: utilization of substantive information from RMG register and evaluation of samples stored in MM bank from pts. with MGUS and MM.
Aims:

  1. Evaluation of pharmacogenomic  and  pharmacoproteomics for the determination of resistance and sensitivity to anti-myeloma drugs
  2. Identification and validation of clinically applicable model for the selection of optimal anti-myeloma treatment on the basis of genomic and proteomic markers
  3. Identification of proteome differences between benign and malignant gammopathies 
  4. Creation of new model superior to currently used systems for the identification of high-risk MGUS patients

10. 11. 2017

Honorary Membership


» Archive